{"schema_version":"secwatch.filing_event.v1","accession":"0001549595-25-000108","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2025-09-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.299009+00:00","generated_at":"2026-05-17T08:30:19.890923+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"medium","headline":"Nurix begins investor meetings with updated clinical plans for bexobrutideg Phase 1 trial","bullets":["Company presenting updated development plans for bexobrutideg (NX-5948), an oral BTK degrader.","Phase 1 trial ongoing in patients with relapsed/refractory B cell malignancies.","Investor presentation dated September 3, 2025, furnished as Exhibit 99.1.","Specific clinical data updates not detailed in the 8-K filing text."],"urls":{"canonical":"https://secwatch.observer/filing/0001549595-25-000108","json":"https://secwatch.observer/filing/0001549595-25-000108.json","markdown":"https://secwatch.observer/filing/0001549595-25-000108.md","text":"https://secwatch.observer/filing/0001549595-25-000108.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000154959525000108/0001549595-25-000108-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000154959525000108/nrix-20250903.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:30:19.890923+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}